Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1

Diabet Med. 2002 Sep;19(9):790-2. doi: 10.1046/j.1464-5491.2002.00657_1.x.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amyloid / blood
  • Amyloid / therapeutic use*
  • Blood Glucose / analysis
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 1 / metabolism
  • Female
  • Glucagon / blood
  • Glucagon / physiology*
  • Glucagon-Like Peptide 1
  • Humans
  • Hyperglycemia / prevention & control
  • Hypoglycemic Agents / therapeutic use*
  • Islet Amyloid Polypeptide
  • Male
  • Peptide Fragments / physiology*
  • Protein Precursors / physiology*

Substances

  • Amyloid
  • Blood Glucose
  • Hypoglycemic Agents
  • Islet Amyloid Polypeptide
  • Peptide Fragments
  • Protein Precursors
  • Glucagon-Like Peptide 1
  • Glucagon
  • pramlintide